Calidi Biotherapeutics/$CLDI
1D1W1MYTD1Y5YMAX
Capital at risk
About Calidi Biotherapeutics
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
- Ticker
- $CLDI
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 29
- Headquarters
- San Diego, United States
- Website
- www.calidibio.com
CLDI Metrics
BasicAdvanced
$4.1M
-
-$33.30
1.33
-
Price and volume
Market cap
$4.1M
Beta
1.33
52-week high
$1.93
52-week low
$1.05
Average daily volume
90K
Financial strength
Current ratio
1.677
Quick ratio
1.258
Long term debt to equity
0.244
Total debt to equity
0.62
Interest coverage (TTM)
-69.73%
Profitability
EBITDA (TTM)
-16.137
Effective tax rate (TTM)
-0.10%
Management effectiveness
Return on assets (TTM)
-134.79%
Return on equity (TTM)
-672.22%
Valuation
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-0.043
Free cash flow yield (TTM)
-2,303.62%
Free cash flow per share (TTM)
-25.335
Growth
Earnings per share change (TTM)
-81.44%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.